使用Trilogy瓣膜经导管主动脉瓣植入治疗症状性原生主动脉瓣反流(ALIGN-AR):关键性、多中心、单臂、研究性器械豁免研究
ALIGN-AR是一项前瞻性、多中心、单臂研究,在美国30个中心纳入700例高外科手术风险的症状性中重度或重度原生主动脉瓣反流患者,使用专用Trilogy瓣膜行经导管主动脉瓣植入(TAVI)。共同主要终点为30天主要不良事件安全复合终点(预设性能目标40.5%)和1年全因死亡率(预设性能目标25.0%)。30天安全复合终点发生率为24.0%(97.5%CI上限27.3%),达到非劣效性能目标;1年全因死亡率为7.7%(97.5%CI上限10.4%),达到优效性能目标。作者认为这些数据支持使用专用器械的TAVI作为高手术风险的原生主动脉瓣反流选定患者的一种可行且有效的治疗选择。
要点
- 30天主要安全复合终点发生率24.0%(97.5%CI上限27.3%),低于预设性能目标40.5%,非劣效检验P<0.0001
- 1年全因死亡率7.7%(97.5%CI上限10.4%),低于预设性能目标25.0%,优效检验P<0.0001;2年全因死亡率13.3%
- 30天复合终点组分:死亡1.6%、卒中1.7%、新起搏器植入21.6%(127/589)、中度主动脉瓣反流0.5%(3/569)、重度主动脉瓣反流0例
- 技术成功率达95%(664/700),中位随访472天(IQR 352-891)
- 作者认为:对于高手术风险的原生主动脉瓣反流选定患者,使用专用器械的TAVI是可行且有效的治疗选择
适用人群与场景
- 美国30个中心纳入的高外科手术风险、症状性中重度或重度原生主动脉瓣反流患者,共700例(关键性队列180例,持续准入队列520例)
- 中位年龄79.0岁(IQR 72.0-84.0);女性321例(46%),男性379例(54%)
- 种族分布:白人532例(76%),黑人或非裔美国人68例(10%),亚裔36例(5%)
诊断标准与关键阈值
- 症状性中重度或重度原生主动脉瓣反流,由研究者判定为高外科手术风险
- 30天主要安全复合终点预设性能目标为40.5%(基于文献报道30%发生率乘以非劣效界值1.35)
- 1年全因死亡率预设性能目标为25.0%
处置流程与药物剂量
- 使用专用Trilogy瓣膜行经导管主动脉瓣植入(TAVI)治疗原生主动脉瓣反流
研究设计与关键结果
- 研究类型:前瞻性、多中心、单臂、研究性器械豁免研究(关键性研究),纳入700例患者,分析基于意向治疗人群
- 干预:使用专用Trilogy瓣膜行TAVI;对照:无同期对照组,采用基于文献的性能目标
- 30天主要安全复合终点(全因死亡、卒中、危及生命或大出血、急性肾损伤、主要血管并发症、需额外外科或经皮干预、新起搏器植入、中度或以上主动脉瓣反流)发生168例(24.0%,97.5%CI上限27.3%),非劣效检验P<0.0001,达到性能目标
- 30天复合终点组分:死亡11例(1.6%),卒中12例(1.7%),新起搏器植入127/589例(21.6%),中度主动脉瓣反流3/569例(0.5%),重度主动脉瓣反流0例
- 1年全因死亡38例(7.7%,97.5%CI上限10.4%),优效检验P<0.0001,达到性能目标;2年全因死亡53例(13.3%)
- 技术成功664/700例(95%);中位随访472天(IQR 352-891)
- 作者报告观察到主动脉瓣反流显著减少、瓣膜血流动力学良好和心肌重构改善,并伴有功能状态和生活质量改善,持续至2年
证据类型、等级与局限
- 证据类型:前瞻性、多中心、单臂、研究性器械豁免关键性研究
- 研究期间:2018年6月8日至2025年7月29日筛查1352例,纳入700例
- 注册号:ClinicalTrials.gov NCT04415047,研究正在进行中
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为:这些数据支持使用专用器械的TAVI作为高手术风险的原生主动脉瓣反流选定患者的一种可行且有效的治疗选择
- 适用人群为高外科手术风险的症状性中重度或重度原生主动脉瓣反流患者;研究未纳入非高手术风险人群
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Transcatheter devices designed for calcific aortic stenosis are not optimised for use in native aortic regurgitation, and data on aortic regurgitation-dedicated platforms are limited. The extended ALIGN-AR pivotal experience with a prospectively enrolled continued-access cohort and longer follow-up aimed to characterise the safety, valve function, and clinical outcomes of transcatheter aortic valve intervention (TAVI) with a dedicated device in aortic regurgitation.
METHODS: ALIGN-AR is a prospective, multicentre, single-arm study enrolling patients at high surgical risk to undergo TAVI with a dedicated valve (Trilogy valve) for symptomatic moderate-to-severe or severe aortic regurgitation at 30 centres in the USA. Coprimary endpoints were a safety composite of major adverse events within 30 days post procedure (all-cause death, stroke, life-threatening or major bleeding, acute kidney injury, major vascular complications, need for additional surgical or percutaneous interventions, new pacemaker implantation, and moderate or greater aortic regurgitation), tested for non-inferiority against a margin of 1·35 applied to literature-based incidence of safety endpoint of 30% translating to performance goal of 40·5%, and 1-year all-cause mortality, tested for superiority against a performance goal of 25·0%. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04415047), and is ongoing.
FINDINGS: Between June 8, 2018, and July 29, 2025, we screened 1352 patients and enrolled 700 patients (pivotal cohort n=180; continued access cohort n=520). Median age was 79·0 years (IQR 72·0-84·0), 321 (46%) were female, 379 (54%) were male, and 532 (76%) were White, 68 (10%) were Black or African American, and 36 (5%) were Asian. Technical success was achieved in 664 (95%) patients. The median duration of follow-up was 472 days (IQR 352-891). The 30-day primary safety composite endpoint occurred in 168 patients (24·0% [upper 97·5% CI 27·3%]; pnon-inferiority<0·0001), meeting the performance goal. Among components of the composite safety endpoint, death occurred in 11 (1·6%), stroke in 12 (1·7%), new pacemaker implantation in 127 (21·6%) of 589, moderate aortic regurgitation in three (0·5%) of 569 and severe aortic regurgitation in none. All-cause mortality occurred in 38 at 1 year (7·7% [upper 97·5% CI 10·4%]; psuperiority<0·0001), meeting the performance goal, and in 53 (13·3%) at 2 years.
INTERPRETATION: In patients with symptomatic moderate-to-severe or severe aortic regurgitation considered to be of high surgical risk, TAVI with a dedicated platform met prespecified safety and effectiveness performance goals. We observed substantial reductions in aortic regurgitation, favourable valve haemodynamics and myocardial remodelling, with associated improvements in functional status and quality-of-life gains up to 2 years. These data support TAVI with a purpose-built device as a feasible and effective treatment option for selected patients with native aortic regurgitation who are at high risk for death or complications after surgery.
FUNDING: JenaValve Technology.
参考来源
- Makkar RR, Thourani VH, Vahl TP, et al. Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study. Lancet. 2025. PMID: 41260228. doi:10.1016/S0140-6736(25)02215-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。